or Try an Advanced Search...

    Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 15.83 -5.72% -0.96
    SNDX closed down 5.72 percent on Friday, November 15, 2024, on 3.76 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical SNDX trend table...
    Date Alert Name Type % Chg
    Volume Surge Other 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Slingshot Bearish Bearish Swing Setup -5.72%
    Calm After Storm Range Contraction -5.72%
    Stochastic Reached Oversold Weakness -5.72%
    Wide Bands Range Expansion -5.72%
    Oversold Stochastic Weakness -5.72%
    Older End-of-Day Signals for SNDX ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Lower Bollinger Band 2 days ago
    Down 5% 2 days ago
    60 Minute Opening Range Breakdown 2 days ago
    Down 3% 2 days ago
    Slingshot Bearish Entry 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    SNDX Chart by TradingView
    Basic chart:

    Profile

    Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Treatment Of Breast Cancer Lung Cancer Cancer Cell Cancer Therapies Hematological Malignancies Pyridines National Cancer Institute Benzamides Histone Deacetylase Inhibitor

    Is SNDX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 Syndax wins FDA approval for leukemia drug revumenib
    Nov 15 Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
    Nov 14 Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
    Nov 13 Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
    Nov 13 Syndax’s revumenib meets primary results in AML trial
    Nov 12 Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
    Nov 12 Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
    Nov 12 Syndax falls after mid-stage data for leukemia drug
    Nov 12 Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
    Nov 8 Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results
    See more SNDX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 25.34
    52 Week Low 14.97
    Average Volume 1,336,463
    200-Day Moving Average 20.91
    50-Day Moving Average 18.87
    20-Day Moving Average 19.03
    10-Day Moving Average 19.06
    Average True Range 1.20
    RSI (14) 32.89
    ADX 20.61
    +DI 21.54
    -DI 37.79
    Chandelier Exit (Long, 3 ATRs) 18.89
    Chandelier Exit (Short, 3 ATRs) 19.11
    Upper Bollinger Bands 22.40
    Lower Bollinger Band 15.65
    Percent B (%b) 0.03
    BandWidth 35.47
    MACD Line -0.47
    MACD Signal Line -0.02
    MACD Histogram -0.4543
    Fundamentals Value
    Market Cap 1.34 Billion
    Num Shares 84.8 Million
    EPS -2.59
    Price-to-Earnings (P/E) Ratio -6.11
    Price-to-Sales 12.67
    Price-to-Book 5.22
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 17.95
    Resistance 3 (R3) 18.07 17.49 17.59
    Resistance 2 (R2) 17.49 16.95 17.43 17.47
    Resistance 1 (R1) 16.66 16.62 16.37 16.54 17.36
    Pivot Point 16.08 16.08 15.94 16.02 16.08
    Support 1 (S1) 15.25 15.54 14.96 15.13 14.30
    Support 2 (S2) 14.67 15.21 14.61 14.19
    Support 3 (S3) 13.84 14.67 14.07
    Support 4 (S4) 13.72